title: Prolonged urokinase infusion for chronic total native coronary occlusions: clinical, angiographic, and treatment observations.
abstract: Prolonged intravascular infusion of urokinase has proven beneficial in reestablishing patency of chronically occluded peripheral arteries and saphenous vein grafts. This study was performed to assess the efficacy and safety of prolonged urokinase infusion as a prelude to angioplasty in chronically occluded native coronary arteries, that had failed standard angioplasty techniques. Twenty-five patients with objective evidence for ischemia in the distribution of a chronic coronary occlusion were referred for percutaneous intervention. Patients were assessed for any potential exclusions from lytic therapy. Urokinase infusion through both a SOS wire and a stable guiding catheter was continued at 100,000-240,000 units/hr for 8-25 hr; patients then underwent attempted balloon angioplasty. Mean duration of urokinase infusion was 20.6 +/- 7.7 hr (total dose 163,000 +/- 52,447 units/hr). Fibrinogen levels dropped slightly with this (300 +/- 129 to 203 +/- 81 mg/dl, P = 0.02). Angiography posturokinase showed improvement in 7 (28%) with regard to coronary flow (> or = 1 TIMI-grade). Angioplasty was successful in 13 (52%), with final angiographic result revealing thrombus in 5 (20%), or dissection 8 (32%). The infusions were well-tolerated with a low incidence of chest pain, 2 (8%) or ischemic ECG response, 2 (8%); myocardial infarction, 2 (8%); or significant bleeding 2 (8%). All patients survived the procedure, with a length-of-hospital stay = 5.1 +/- 4 days. Use of prolonged preangioplasty intracoronary urokinase infusion can be done safely with success in roughly one-half of patients with chronic total native coronary occlusions who have failed prior attempts at percutaneous intervention.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: William Beaumont Hospital, Royal Oak, Michigan.
authors.forename: S C
authors.initials: SC
authors.lastname: Ajluni
authors.forename: D
authors.initials: D
authors.lastname: Jones
authors.forename: F
authors.initials: F
authors.lastname: Zidar
authors.forename: S
authors.initials: S
authors.lastname: Puchrowicz
authors.forename: A
authors.initials: A
authors.lastname: Margulis
authors.forename: W W
authors.initials: WW
authors.lastname: O'Neill
authors.forename: C L
authors.initials: CL
authors.lastname: Grines
mesh_terms: D000328:Adult; D000368:Aged; D000784:Aortic Dissection / Q000000981:diagnostic imaging; D000787:Angina Pectoris / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015906:Angioplasty, Balloon, Coronary; D002908:Chronic Disease; D003131:Combined Modality Therapy; D003323:Coronary Aneurysm / Q000000981:diagnostic imaging; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D004334:Drug Administration Schedule; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D014568:Urokinase-Type Plasminogen Activator